Cabotegravir Bests TDF-FTC for HIV Prevention in Those at Risk
THURSDAY, Aug. 12, 2021 -- For men who have sex with men (MSM) and transgender women, long-acting injectable cabotegravir (CAB-LA, an integrase strand-transfer inhibitor [INSTI]) is superior to tenofovir disoproxil fumarate-emtricitabine (TDF-FTC)... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 12, 2021 Category: Pharmaceuticals Source Type: news

Dolutegravir Confirmed as Effective Second-Line HIV Therapy Dolutegravir Confirmed as Effective Second-Line HIV Therapy
A new randomized trial bolsters efficacy evidence for dolutegravir and finds no benefit in switching from tenofovir in second-line HIV treatment.Medscape Medical News (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - July 22, 2021 Category: Infectious Diseases Tags: HIV/AIDS News Source Type: news

Symfi Lo (Efavirenz, Lamivudine and Tenofovir Disoproxil Fumarate Tablets) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - July 19, 2021 Category: Drugs & Pharmacology Source Type: news

Both HIV and Tenofovir Tied to Skeletal Deficits in Young People Both HIV and Tenofovir Tied to Skeletal Deficits in Young People
HIV is associated with'substantial'skeletal deficits toward the end of puberty, especially among girls, as is the antiretroviral tenovir disoproxil fumarate, a cross-sectional study shows.Reuters Health Information (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - July 7, 2021 Category: Infectious Diseases Tags: HIV/AIDS News Source Type: news

Effectiveness and Renal Safety of TAF in Chronic HBV Effectiveness and Renal Safety of TAF in Chronic HBV
How does the renal safety of tenofovir alafenamide fumarate compare to that of tenofovir disoproxil fumarate in a real-world clinical setting? Can switching from TDF to TAF reverse renal impairment?Journal of Viral Hepatitis (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - July 6, 2021 Category: Intensive Care Tags: Gastroenterology Journal Article Source Type: news

Outcomes Associated With Change From TDF to TAF in HIV-1 Outcomes Associated With Change From TDF to TAF in HIV-1
A new study looks at the effects of a treatment switch from tenofovir disoproxil fumarate to tenofovir alafenamide-containing ART regimens among HIV-1-infected patientsHIV Medicine (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - July 1, 2021 Category: Infectious Diseases Tags: HIV/AIDS Journal Article Source Type: news

Temixys (lamivudine and tenofovir disoproxil fumarate)
Title: Temixys (lamivudine and tenofovir disoproxil fumarate)Category: MedicationsCreated: 6/16/2021 12:00:00 AMLast Editorial Review: 6/16/2021 12:00:00 AM (Source: MedicineNet HIV General)
Source: MedicineNet HIV General - June 16, 2021 Category: Infectious Diseases Source Type: news

HIV has detrimental effect on children ’ s growth and bone strength, finds landmark study
Children growing up with HIV infection have concerning deficits in skeletal strength which become more apparent towards the end of pubertal growth, finds the largest study to date to investigate the link between HIV and skeletal health in children. The study, conducted in Zimbabwe and published in The Lancet Child and Adolescent Health, identifies a link between these skeletal deficits and the first-line antiretroviral-HIV drug, tenofovir disproxil fumarate (TDF), which is widely used across sub-Saharan Africa. (Source: University of Bristol news)
Source: University of Bristol news - June 14, 2021 Category: Universities & Medical Training Tags: Research, International, Health; Faculty of Health Sciences, Faculty of Health Sciences, Bristol Medical School; Press Release Source Type: news

Lupin gets USFDA nod to market generic HIV drug
The company has received approval from the United States Food and Drug Administration (USFDA) to market its Emtricitabine and Tenofovir Disoproxil Fumarate tablets, 200 mg/300 mg, Lupin said in a regulatory filing. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - June 7, 2021 Category: Pharmaceuticals Source Type: news

Complera (emtricitabine, rilpivirine, tenofovir disoproxil fumarate)
Title: Complera (emtricitabine, rilpivirine, tenofovir disoproxil fumarate)Category: MedicationsCreated: 5/27/2021 12:00:00 AMLast Editorial Review: 5/27/2021 12:00:00 AM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - May 27, 2021 Category: Drugs & Pharmacology Source Type: news

Symtuza (darunavir, cobicistat, emtricitabine, and tenofovir alafenamide)
Title: Symtuza (darunavir, cobicistat, emtricitabine, and tenofovir alafenamide)Category: MedicationsCreated: 4/30/2021 12:00:00 AMLast Editorial Review: 4/30/2021 12:00:00 AM (Source: MedicineNet HIV General)
Source: MedicineNet HIV General - April 30, 2021 Category: Infectious Diseases Source Type: news

Replacing TDF With TAF for HIV Tied to Adverse Metabolic Changes
FRIDAY, April 9, 2021 -- For people with HIV receiving tenofovir-based antiretroviral therapy (ART), replacing tenofovir disoproxil fumarate (TDF) with tenofovir alafenamide (TAF) is associated with adverse metabolic changes, including weight... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 9, 2021 Category: Pharmaceuticals Source Type: news

Study Reinforces Need to Monitor Kidney Function in Long-Term PrEP Users Study Reinforces Need to Monitor Kidney Function in Long-Term PrEP Users
In people taking tenofovir-based PrEP, established biomarkers of kidney injury may be elevated in patients with and without clinical evidence of kidney injury, researchers have found.Reuters Health Information (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - April 6, 2021 Category: Infectious Diseases Tags: HIV/AIDS News Source Type: news

Dyslipidemia After Switch to TAF-Based cART in HIV Patients Dyslipidemia After Switch to TAF-Based cART in HIV Patients
Switching from tenofovir to tenofovir alafenamide may cause lipid profile changes in HIV patients. What are the clinical implications?HIV Medicine (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - March 17, 2021 Category: Infectious Diseases Tags: HIV/AIDS Journal Article Source Type: news

Certain HIV Meds May Trigger Weight Gain
New research raises questions about one drug featured in many ART recipes: tenofovir alafenamide, also known as TAF. (Source: WebMD Health)
Source: WebMD Health - March 16, 2021 Category: Consumer Health News Source Type: news

Strides Pharma Science arm gets USFDA nod for HIV treatment drug
Drug firm Strides Pharma Science on Friday said its step-down wholly-owned subsidiary, Strides Pharma Global, has received approval from the US health regulator for Emtricitabine and Tenofovir Disoproxil Fumarate tablets, used to treat HIV. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - January 15, 2021 Category: Pharmaceuticals Source Type: news

Tenofovir Alafenamide vs. Tenofovir Disoproxil Fumarate Tenofovir Alafenamide vs. Tenofovir Disoproxil Fumarate
How do these two antiretroviral regimens for HIV compare in terms of safety and efficacy?AIDS (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - December 4, 2020 Category: Infectious Diseases Tags: HIV/AIDS Journal Article Source Type: news

MTX Decreases Tenofovir Exposure in ART-Suppressed HIV MTX Decreases Tenofovir Exposure in ART-Suppressed HIV
A new study finds that methotrexate may alter tenofovir exposure among virally suppressed people living with HIV. Does this warrant a change in dosing during the co-administration of these drugs?JAIDS: Journal of Acquired Immune Deficiency Syndromes (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - November 30, 2020 Category: Infectious Diseases Tags: HIV/AIDS Journal Article Source Type: news

Mixed Outcomes in Tenofovir Trial for Chronic Hepatitis B Mixed Outcomes in Tenofovir Trial for Chronic Hepatitis B
Levels of surface antigen loss were low whether or not patients treated with tenofovir also received interferon, but some patients met criteria for inactive chronic disease after therapy withdrawal.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 15, 2020 Category: Consumer Health News Tags: Gastroenterology News Source Type: news

eGFR Slopes on Tenofovir Alafenamide eGFR Slopes on Tenofovir Alafenamide
Did individuals switching to a tenofovir alafenamide-containing ART regimen realize improvement in eGFR slope?HIV Medicine (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - November 13, 2020 Category: Infectious Diseases Tags: HIV/AIDS Journal Article Source Type: news

Stribild (elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate)
Title: Stribild (elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate)Category: MedicationsCreated: 10/28/2020 12:00:00 AMLast Editorial Review: 10/28/2020 12:00:00 AM (Source: MedicineNet HIV General)
Source: MedicineNet HIV General - October 28, 2020 Category: Infectious Diseases Source Type: news

Odefsey (emtricitabine, rilpivirine, and tenofovir alafenamide)
Title: Odefsey (emtricitabine, rilpivirine, and tenofovir alafenamide)Category: MedicationsCreated: 10/6/2020 12:00:00 AMLast Editorial Review: 10/6/2020 12:00:00 AM (Source: MedicineNet HIV General)
Source: MedicineNet HIV General - October 6, 2020 Category: Infectious Diseases Source Type: news

Insurer, Insured Costs for HIV PrEP Rising in the United States
WEDNESDAY, Sept. 9, 2020 -- From 2014 to 2018, there were increases noted in third-party and out-of-pocket (OOP) payments per 30 tenofovir disoproxil fumarate with emtricitabine (TDF-FTC) tablets for HIV preexposure prophylaxis (PrEP), according to... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 9, 2020 Category: Pharmaceuticals Source Type: news

' Vacation PrEP': Short-Term HIV Prevention a Viable Option
THURSDAY, Aug. 27, 2020 -- The daily use of antiretroviral meds to help prevent HIV infection has been around for a few years now -- it's called pre-exposure prophylaxis, or PrEP. PrEP includes combo drugs such as Truvada (tenofovir/emtricitabine).... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - August 27, 2020 Category: General Medicine Source Type: news

Renal Dysfunction Improves Following Tenofovir Type Switch: Study Renal Dysfunction Improves Following Tenofovir Type Switch: Study
In HIV/HBV-coinfected individuals with renal dysfunction, renal function improves after switching from tenofovir disoproxil fumarate to tenofovir alafenamide, according to results from a prospective study.Reuters Health Information (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - August 19, 2020 Category: Infectious Diseases Tags: HIV/AIDS News Source Type: news

Weight Gain Persists as HIV-Treatment Issue Weight Gain Persists as HIV-Treatment Issue
Reports have rattled the HIV-treatment community by associating alarmingly high levels of weight gain with a useful and relatively new drug, tenofovir alafenamide fumarate.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - August 7, 2020 Category: Endocrinology Tags: Infectious Diseases News Source Type: news

Switching TDF to TAF in a Real Life Setting Switching TDF to TAF in a Real Life Setting
Are there benefits to an ART switch from tenofovir disoproxil fumarate to tenofovir alafenamide?HIV Medicine (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - July 10, 2020 Category: Infectious Diseases Tags: HIV/AIDS Journal Article Source Type: news

HPTN 083 study demonstrates superiority of cabotegravir for the prevention of HIV
(FHI360) The HPTN 083 clinical trial showed that a pre-exposure prophylaxis (PrEP) regimen containing long-acting cabotegravir (CAB LA) injected once every 8 weeks was superior to daily oral tenofovir/emtricitabine (TDF/FTC) for HIV prevention among cisgender men and transgender women who have sex with men. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - July 7, 2020 Category: Infectious Diseases Source Type: news

Genvoya (elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide)
Title: Genvoya (elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide)Category: MedicationsCreated: 4/17/2020 12:00:00 AMLast Editorial Review: 4/17/2020 12:00:00 AM (Source: MedicineNet HIV General)
Source: MedicineNet HIV General - April 17, 2020 Category: Infectious Diseases Source Type: news

Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide)
Title: Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide)Category: MedicationsCreated: 4/16/2020 12:00:00 AMLast Editorial Review: 4/16/2020 12:00:00 AM (Source: MedicineNet HIV General)
Source: MedicineNet HIV General - April 16, 2020 Category: Infectious Diseases Source Type: news

Safety of TAF in Patients With Tubulopathy on TDF Safety of TAF in Patients With Tubulopathy on TDF
Is tenofovir alafenamide a safe and effective option for HIV patients with a history of tenofovir disoproxil fumarate-associated tubulopathy?HIV Medicine (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - March 25, 2020 Category: Infectious Diseases Tags: HIV/AIDS Journal Article Source Type: news

Lack of evidence to support use of darunavir-based treatments for SARS-CoV-2
Anecdotal, unsubstantiated reports claim that darunavir has antiviral effect against COVID-19Johnson & Johnson has no evidence that darunavir has any effect against SARS-CoV-2, the virus that causes COVID-19Johnson & Johnson is screening its antiviral compounds, including darunavir, to determine potential in vitro effect against SARS-CoV-2We are partnering with multiple organizations to support the development of research programs and fast-track solutions for COVID-19Considering the large public health and humanitarian implications, we are committed to global efforts to care for those affected, contain the current ...
Source: Johnson and Johnson - March 16, 2020 Category: Pharmaceuticals Tags: Corporate Source Type: news

New HIV PrEP Drug Not Cost-Effective Compared With Generic
WEDNESDAY, March 11, 2020 -- Use of tenofovir alafenamide-emtricitabine (F/TAF) is not cost-effective compared with generic tenofovir disoproxil fumarate-emtricitabine (F/TDF) for HIV preexposure prophylaxis (PrEP) among men who have sex with men... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 11, 2020 Category: Pharmaceuticals Source Type: news

Newer anti-HIV drugs safest, most effective during pregnancy
(NIH/National Institute of Allergy and Infectious Diseases) The antiretroviral drugs dolutegravir and emtricitabine/tenofovir alafenamide fumarate (DTG+FTC/TAF) may comprise the safest and most effective HIV treatment regimen currently available during pregnancy, researchers announced today. Their findings come from a multinational study of more than 640 pregnant women with HIV across four continents. The current study compared three antiretroviral drug regimens and found that regimens containing dolutegravir (DTG) were more effective in suppressing HIV than a commonly used regimen containing efavirenz (EFV). (Source: Eure...
Source: EurekAlert! - Medicine and Health - March 11, 2020 Category: International Medicine & Public Health Source Type: news

NIH study finds lower concentration of PrEP drug in pregnant young women
(NIH/National Institute of Allergy and Infectious Diseases) Among African adolescent girls and young women who took HIV pre-exposure prophylaxis (PrEP) daily, levels of the PrEP drug tenofovir were more than 30% lower in those who were pregnant than in those who had recently given birth. All 40 study participants took PrEP under direct observation, confirming their near-perfect adherence. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 9, 2020 Category: International Medicine & Public Health Source Type: news

Emtricitabine/tenofovir alafenamide not cost effective despite fewer AEs
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - February 29, 2020 Category: Drugs & Pharmacology Source Type: news

NPPA seeks clarification on Gilead's drug pricing plea
National Pharmaceutical Pricing Authority has sought clarifications from the company. Gilead had sought exemption from price control for its Tenofovir Alafenamide tablets (brand name Vemlidy) to capture a major chunk of Rs 140-crore market for chronic Hepatitis B in India. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - January 30, 2020 Category: Pharmaceuticals Source Type: news

D/C/F/TAF Tablet Effective Rapid-Initiation HIV Treatment D/C/F/TAF Tablet Effective Rapid-Initiation HIV Treatment
The single-tablet combination of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) is effective for treating newly diagnosed HIV-1 infection before baseline laboratory results are available, according to results from the DIAMOND phase-3 study.Reuters Health Information (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - January 21, 2020 Category: Infectious Diseases Tags: HIV/AIDS News Source Type: news

Four-Drug Combination Effective Long-Term for HIV Suppression Four-Drug Combination Effective Long-Term for HIV Suppression
The single-tablet combination of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) is effective for long-term viral suppression in previously untreated patients with HIV-1 infection, according to 96-week results from the AMBER trial.Reuters Health Information (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - January 3, 2020 Category: Infectious Diseases Tags: HIV/AIDS News Source Type: news

Nigeria: HIV - Experts Urge Increased Awareness On Anti-Retroviral Drug
[Daily Trust] Experts have called for increased enlightenment on the anti- retroviral drug, Tenofovir/Lamivudine/Dolutegravir (TLD). (Source: AllAfrica News: HIV-Aids and STDs)
Source: AllAfrica News: HIV-Aids and STDs - December 30, 2019 Category: Infectious Diseases Source Type: news

Activists and LGBTQ Groups Say These Facebook Ads Spread Dangerous Misinformation About HIV Drugs
Advocacy groups are urging Facebook to remove advertisements that they say unfairly infer that the HIV/AIDS prevention Truvada PrEP (pre-exposure prophylaxis) is dangerous, an allegation they say could endanger the people who are most at risk of contracting the disease. More than 50 HIV/AIDs, LGBTQ and public health advocacy groups released a letter on Monday asking Facebook and Instagram to remove the ads from their platforms. The ads referred specifically to “Truvada PrEP” (the brand name for one of the medications, dtenofovir disoproxil fumarate, used as PrEP) and in some cases more generically to “PrE...
Source: TIME: Health - December 11, 2019 Category: Consumer Health News Authors: Tara Law Tags: Uncategorized health LGBTQ onetime Source Type: news

FDA Approves Descovy (emtricitabine and tenofovir alafenamide) for HIV Pre-Exposure Prophylaxis (PrEP)
FOSTER CITY, Calif.--(BUSINESS WIRE)--Oct. 3, 2019-- Gilead Sciences, Inc. (NASDAQ: GILD) today announced that the U.S. Food and Drug Administration (FDA) approved a pre-exposure prophylaxis (PrEP) indication for Descovy... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - October 3, 2019 Category: Drugs & Pharmacology Source Type: news

FDA OKs Descovy, Second Drug for HIV PrEP FDA OKs Descovy, Second Drug for HIV PrEP
The combo of emtricitabine and tenofovir alafenamide is indicated to reduce the risk for HIV-1 infection from sex (excluding receptive vaginal sex) in at-risk adults and teens weighing at least 35 kg.FDA Approvals (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - October 3, 2019 Category: Infectious Diseases Tags: HIV/AIDS News Alert Source Type: news

FDA approves second drug to prevent HIV infection as part of ongoing efforts to end the HIV epidemic
The U.S. Food and Drug Administration today approved Descovy (emtricitabine 200 mg and tenofovir alafenamide 25 mg) in at-risk adults and adolescents weighing at least 35kg for HIV-1 pre-exposure prophylaxis (PrEP) to reduce the risk of HIV-1 infection from sex, excluding those who have receptive vaginal sex. (Source: World Pharma News)
Source: World Pharma News - October 3, 2019 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

Delstrigo (Doravirine, Lamivudine, and Tenofovir Disoproxil Fumarate Tablets) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - September 30, 2019 Category: Drugs & Pharmacology Source Type: news

Merck ’s Pifeltro (doravirine) and Delstrigo (doravirine/lamivudine/tenofovir disoproxil fumarate) Receive FDA Approval for Use in Appropriate Adults Living with HIV-1 Who Are Virologically Suppressed
KENILWORTH, N.J.--(BUSINESS WIRE) September 20, 2019 --Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) approved supplemental New Drug Applications (sNDAs) for... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - September 20, 2019 Category: Drugs & Pharmacology Source Type: news

Weight Gain on INSTI-based HIV Antiretrovirals Weight Gain on INSTI-based HIV Antiretrovirals
Dolutegravir and tenofovir alafenamide can lead to weight gain, especially in women, according to new data that are changing the way researchers look at their study populations.Medscape Medical News (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - July 26, 2019 Category: Infectious Diseases Tags: HIV/AIDS News Source Type: news

Minor Changes in BMD Seen With Tenofovir PrEP in Short Term
WEDNESDAY, July 24, 2019 -- Tenofovir preexposure prophylaxis (PrEP) therapy does not appear to be associated with clinically significant declines in bone mineral density (BMD) in the short term, according to a study published online June 19 in AIDS... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - July 25, 2019 Category: Pharmaceuticals Source Type: news

Lower than expected risk of bone density decline with Truvada PrEP
(Mary Ann Liebert, Inc./Genetic Engineering News) Researchers have shown that among users of pre-exposure prophylaxis (PrEP) to prevent against AIDS that includes tenofovir (Truvada), those with daily use -- very high adherence -- had only about a 1% average decrease in bone mineral density in the spine and a 0.5% decline in the hip. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 15, 2019 Category: International Medicine & Public Health Source Type: news

Zambia: Govt Gets TAF On HIV
[Times of Zambia] The government has launched a new HIV drug called Tenofovir Alafenamide (TAF) which is said to have fewer side effects on bones and kidney and can suppress viral loads within 10-14 days. (Source: AllAfrica News: HIV-Aids and STDs)
Source: AllAfrica News: HIV-Aids and STDs - July 2, 2019 Category: Infectious Diseases Source Type: news